Press Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 9, 2020Launched Phexxi™ (lactic acid, citric acid, potassium bitartrate) in U.S. for Hormone-free Contraception
-
Oct 27, 2020-- Conference Call Scheduled for 5:00 p.m. ET --
-
Oct 26, 2020- Live moderated video webcast discussion with members of Evofem management and Key Opinion Leader Patty Cason, RN, MS, FNP-BC, on Thursday, October 29th at 2:00 p.m. ET -
-
Sep 14, 2020- Company plans to initiate Phase 3 STI trial by the end of 2020 -
-
Sep 8, 2020- A First-in-Class Vaginal pH Modulator Designed for Use "In-the-Moment" -
-
Aug 4, 2020- Advancing Precommercial Activities in Preparation for Phexxi™ Commercial Launch in September 2020 -
-
Jul 23, 2020-- Conference Call Scheduled for 11:00 a.m. EDT --
-
Jul 1, 2020- On-Track for September Launch of Phexxi™, the First FDA-Approved, Non-Hormonal, On-Demand Prescription Contraceptive Gel -
-
May 22, 2020- A New Class of Female-Controlled Birth Control for Use In-The-Moment -
-
May 6, 2020- On-Track for Phexxi™ PDUFA Date: May 25, 2020 -
-
Apr 28, 2020-- Conference Call Scheduled for 11:00 a.m. ET --
-
Apr 27, 2020- Funding to Support the Company's Launch and Commercialization Plans for Phexxi™ -
-
Apr 24, 2020- Perfect Use Efficacy Up to 93.3%; Exploratory Findings Demonstrate Increased Sexual Satisfaction and Vaginal Lubrication; Company Provides Updated Safety Outcomes -